Background & Aims

Previous research in the Madsen Lab have led to the development of a lipidated peptide inhibitor of neuronal synaptic plasticity that alleviates neuropathic pain in preclinical models. Here we applied an innovative labeling technique in combination with tissue clearing and 3D imaging to visualise the tissue distribution of the peptide inhibitor.

Methods

We labeled the peptide inhibitor with the VivoTag flurorescent dye from Revvity and, after subcutanoues administration in naïve and spared nerve injury (SNI) mice, applied tissue clearing and 3D imaging techniques to visualize the VivoTag-peptide distribution in the neural systems.

Results

Following a subcutaneous injection of the VivoTag-peptide, the predominant localization is in peripheral tissues, with undetectable levels in the spinal cord and brain. This observation, in concert with other findings from our lab, suggests that the peptide has a potential impact on peripheral neurons.

Conclusions

These findings are important in the context of existing neuropathic pain treatments, as these primarily target the central nervous system (CNS), often resulting in prominent adverse effects. The peripheral retention of the VivoTag-peptide makes it a promising candidate for relieving neuropathic pain with potentially fewer side effects.

References

NA

Presenting Author

Ida Buur Kanneworff

Poster Authors

Ida Buur Kanneworff

MSc

University of Copenhagen

Lead Author

Sara E. Jager

PhD

University of Copenhagen

Lead Author

Grace A Houser PhD

University of Copenhagen

Lead Author

Kathrine Louise Jensen PhD

University of Copenhagen

Lead Author

Kenneth Lindegaard Madsen PhD

University of Copenhagen

Lead Author

Topics

  • Pain Imaging